HaemaLogiX and Lonza Collaborate to Manufacture KappaMab, a Multiple Myeloma Drug Candidate
- Written by PR Newswire
- Lonza to manufacture drug substance for clinical supply of HaemaLogiX's lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou (CN)
- HaemaLogiX will leverage Lonza's regulatory expertise, global manufacturing footprint, and extensive experience in manufacturing monoclonal antibodies
BASEL, Switzerland and SY...
